Your browser version may not work well with NCBI's Web applications. More information here...
1: Crit Care. 2008;12(3):153. Epub 2008 May 29.Click here to read Click here to read Links
Comment on:
Crit Care. 2008;12(2):R61.

Progesterone in traumatic brain injury: time to move on to phase III trials.

Vandromme M, Melton SM, Kerby JD.

Section of Trauma, Burns, and Surgical Critical Care, Department of Surgery, University of Alabama at Birmingham, 19th Street South, Birmingham, Alabama 35294, USA.

There are several candidate neuroprotective agents that have been shown in preclinical testing to improve outcomes following traumatic brain injury (TBI). Xiao and colleagues have performed an in hospital, double blind, randomized, controlled clinical trial utilizing progesterone in the treatment of patients sustaining TBI evaluating safety and long term clinical outcomes. These data, combined with the results of the previously published ProTECT trial, show progesterone to be safe and potentially efficacious in the treatment of TBI. Larger phase III trials will be necessary to verify results prior to clinical implementation. Clinical trials networks devoted to the study of TBI are vital to the timely clinical testing of these candidate agents and need to be supported.

PMID: 18522765 [PubMed - indexed for MEDLINE]

PMCID: PMC2481452

Patient Drug Information

  • Progesterone (Prometrium® )

    Progesterone is used as a part of hormone replacement therapy in women who have passed menopause (the change of life) and have not had a hysterectomy (surgery to remove the uterus). Hormone replacement therapy usually in...

  • Source: AHFS Consumer Medication Information